Physicians' Academy for Cardiovascular Education

Lp(a), a new lipid frontier in CV risk management & target for therapy

Meeting report with presentation slides, videos and online CME of a PACE-CME symposium held during ESC 2020, The Digital Experience.

E-learning Lp(a), a new lipid frontier in CV risk management

EBAC-accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

This online course covers different aspects of lipoprotein(a) (Lp(a)): the pathophysiology, its role in CVD risk and (novel) therapeutic options to reduce Lp(a) levels.

Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

10' education - Nov. 3, 2020 - Prof. Erik Stroes, MD
Prof. Stroes gives an introduction to the symposium about different aspects of lipoprotein(a) (Lp(a)), that was held during the virtual ESC 2020 congress.

Prof. Stroes gives an introduction to the symposium about different aspects of lipoprotein(a) (Lp(a)), that was held during the virtual ESC 2020 congress.

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD
Prof. Bittner summarizes findings from post-hoc analyses of FOURIER and ODYSSEY OUTCOMES on the relationship between Lp(a) lowering by PCSK9i and CV risk.

Prof. Bittner summarizes findings from post-hoc analyses of FOURIER and ODYSSEY OUTCOMES on the relationship between Lp(a) lowering by PCSK9 inhibition and CV risk.

Novel strategies to lower Lp(a)

10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD
RNA therapeutics can reduce production of apo(a) in hepatocyten and thereby prevent assembly of Lp(a). This presentation provides an overview of phase 2 studies with antisense mediated Lp(a) lowering.

RNA therapeutics can reduce production of apo(a) in hepatocyten and thereby prevent assembly of Lp(a). This presentation provides an overview of phase 2 studies with antisense mediated Lp(a) lowering.

Why worry about high Lp(a) and how to assess Lp(a) levels?

10' education - Oct. 7, 2020 - Pia Kamstrup, MD, PhD
High Lp(a) levels are associated with increased risk of CV events. Pia Kamstrup presents the evidence from studies and in addition talks about challenges when determining Lp(a) levels.

High Lp(a) levels are associated with increased risk of CV events. Pia Kamstrup presents the evidence from studies and in addition talks about challenges when determining Lp(a) levels.

Discussion: Lp(a), a new lipid frontier in CV risk management & target for therapy.

Oct. 6, 2020

Expert discussion on Lp(a), a new lipid frontier in CV risk management & target for therapy.

Lp(a), a new lipid frontier in CV risk management & target for therapy